Host |
Rabbit |
Klon |
ZR274 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 625-738) of human CD31 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface and cytoplasm |
CD31
|
Zeta Corporation |
ZR274 |
7 ml |
Concentrate |
CE/IVD |
Z2725RP |
-
|
Host |
Rabbit |
Klon |
ZR274 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 625-738) of human CD31 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface and cytoplasm |
CD31
|
Zeta Corporation |
ZR274 |
0.5 ml |
Concentrate |
CE/IVD |
Z2725RS |
-
|
Host |
Rabbit |
Klon |
ZR274 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 625-738) of human CD31 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface and cytoplasm |
CD31
|
Zeta Corporation |
ZR274 |
0.1 ml |
Concentrate |
CE/IVD |
Z2725RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of mouse CD31 protein. |
Lokalisation |
Cell Membrane |
CD31 (PECAM-1)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-11114 |
-
|
Host |
Mouse |
Klon |
JC/70A |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
1 ml |
Concentrate |
CE/IVD |
MOB034 |
-
|
Host |
Mouse |
Klon |
JC/70A |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
0.1 ml |
Concentrate |
CE/IVD |
MOB034-01 |
-
|
Host |
Mouse |
Klon |
JC/70A |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
0.5 ml |
Concentrate |
CE/IVD |
MOB034-05 |
-
|
Host |
Mouse |
Klon |
JC/70A |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
6 ml |
Ready-to-use |
CE/IVD |
PDM020 |
-
|
Host |
Mouse |
Klon |
CO.3E1D4 |
Format |
Purified |
Methode |
FL |
Isotyp |
Mouse IgG2a |
Verdünnung |
Sheep leucocytes |
CD31 (PECAM-1) - FITC
|
Zytomed Systems GmbH |
CO.3E1D4 |
100 µg |
Purified |
RUO |
603-0798C |
-
|
Host |
Mouse |
Klon |
PWS44 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Myeloid leukemia |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG2b |
Lokalisation |
Cytoplasm and Cell Membrane |
CD33
|
Biocare Medical |
PWS44 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3116A |
-
|
Host |
Mouse |
Klon |
PWS44 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Myeloid leukemia |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG2b |
Lokalisation |
Cytoplasm and Cell Membrane |
CD33
|
Biocare Medical |
PWS44 |
1 ml |
Concentrate |
CE/IVD |
ACI3116C |
-
|
Host |
Mouse |
Klon |
PWS44 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Myeloid leukemia |
Verdünnung |
- |
Isotyp |
Mouse IgG2b |
Lokalisation |
Cytoplasm and Cell Membrane |
CD33
|
Biocare Medical |
PWS44 |
6 ml |
Ready-to-use |
CE/IVD |
API3116AA |
-
|
Host |
Mouse |
Klon |
QBEnd/10 |
Format |
ready-to-use |
Methode |
IHC, FFPE |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
Tonsil, skin or angiosarcoma |
Verdünnung |
--- |
Isotyp |
IgG1 |
Verdünnung |
CD34 |
Lokalisation |
Cell surface and cytoplasmic |
CD34
|
Biocare Medical |
QBEnd/10 |
6 ml |
ready-to-use |
CE/IVD |
AVI084G |
-
|
Host |
Mouse |
Klon |
QBend/10 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
1 ml |
Concentrate |
CE/IVD |
MOB098 |
-
|
Host |
Mouse |
Klon |
QBend/10 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB098-01 |
-
|
Host |
Mouse |
Klon |
QBend/10 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB098-05 |
-
|
Host |
Mouse |
Klon |
QBend/10 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
6 ml |
Ready-to-use |
CE/IVD |
PDM050 |
-
|
Host |
Mouse |
Klon |
QBEnd-10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hemangioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
Lokalisation |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
1.0 ml |
Concentrate |
CE/IVD |
Z2063ML |
-
|
Host |
Mouse |
Klon |
QBEnd-10 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hemangioma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
Lokalisation |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2063MP |
-
|
Host |
Mouse |
Klon |
QBEnd-10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hemangioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
Lokalisation |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2063MS |
-
|
Host |
Mouse |
Klon |
QBEnd-10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hemangioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
Lokalisation |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2063MT |
-
|
Host |
Rat |
Klon |
MEC14.7 |
Format |
Purified |
Methode |
IP, FL |
Isotyp |
Rat IgG2a |
CD34 (Endothelial Cell) (Low Endotoxin)
|
Zytomed Systems GmbH |
MEC14.7 |
500 µg |
Purified |
RUO |
603-0832 |
-
|
Host |
Mouse |
Klon |
QBEND/10 |
Format |
Purified |
Methode |
FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human endothelial cell membrane vesicles |
CD34 (Endothelial Cell) - FITC
|
Zytomed Systems GmbH |
QBEND/10 |
100 Tests |
Purified |
RUO |
603-0845C |
-
|
Host |
Rabbit |
Klon |
SP191 |
Methode |
IHC-P |
Verdünnung |
1:100 |
CD35
|
Zytomed Systems GmbH |
SP191 |
1 ml |
- |
RUO |
503-4914 |
-
|
Host |
Mouse |
Klon |
E11 |
Format |
Purified |
Methode |
F, P, WB, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Human Tonsil |
Verdünnung |
1-10 µg/mL (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human acute monocytic leukemia cells |
CD35 (CR1)
|
Zytomed Systems GmbH |
E11 |
100 µg |
Purified |
RUO |
603-0851 |
-
|
Host |
Rabbit |
Klon |
SP149 |
Format |
Concentrate |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of human CD38 protein. |
Lokalisation |
Cell membrane |
CD38
|
Zytomed Systems GmbH |
SP149 |
0.1 ml |
Concentrate |
RUO |
503-4490 |
-
|
Host |
Rabbit |
Klon |
SP149 |
Format |
Concentrate |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of human CD38 protein. |
Lokalisation |
Cell membrane |
CD38
|
Zytomed Systems GmbH |
SP149 |
0.5 ml |
Concentrate |
RUO |
503-4492 |
-
|
Host |
Rabbit |
Klon |
SP149 |
Format |
Concentrate |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of human CD38 protein. |
Lokalisation |
Cell membrane |
CD38
|
Zytomed Systems GmbH |
SP149 |
1 ml |
Concentrate |
RUO |
503-4494 |
-
|
Host |
Rabbit |
Klon |
ZR351 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Peptide derived from the C-terminus of human CD38 protein |
Lokalisation |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
1 ml |
Concentrate |
CE/IVD |
Z2610RL |
-
|
Host |
Rabbit |
Klon |
ZR351 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Peptide derived from the C-terminus of human CD38 protein |
Lokalisation |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
7 ml |
Ready-to-use |
CE/IVD |
Z2610RP |
-
|
Host |
Rabbit |
Klon |
ZR351 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Peptide derived from the C-terminus of human CD38 protein |
Lokalisation |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
0.5 ml |
Concentrate |
CE/IVD |
Z2610RS |
-
|
Host |
Rabbit |
Klon |
ZR351 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Peptide derived from the C-terminus of human CD38 protein |
Lokalisation |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
0.1 ml |
Concentrate |
CE/IVD |
Z2610RT |
-
|
Host |
Mouse |
Klon |
AT13/5 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Mouse IgG1 |
CD38 (Azide Free)
|
Zytomed Systems GmbH |
AT13/5 |
1 mg |
Purified |
RUO |
603-0870F |
-
|
Host |
Mouse |
Klon |
GRP-P |
Format |
Lyophilised |
Methode |
FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human red blood cells and platelets |
CD42a - RPE
|
Zytomed Systems GmbH |
GRP-P |
100 Tests |
Lyophilised |
RUO |
603-0925E |
-
|
Host |
Rabbit |
Klon |
SP202 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bone Marrow, Spleen |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from human CD42b protein |
Lokalisation |
Cell Membrane |
CD42b
|
Zytomed Systems GmbH |
SP202 |
0.1 ml |
Concentrate |
RUO |
503-5020 |
-
|
Host |
Rabbit |
Klon |
SP202 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bone Marrow, Spleen |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from human CD42b protein |
Lokalisation |
Cell Membrane |
CD42b
|
Zytomed Systems GmbH |
SP202 |
0.5 ml |
Concentrate |
RUO |
503-5022 |
-
|
Host |
Rabbit |
Klon |
SP202 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bone Marrow, Spleen |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from human CD42b protein |
Lokalisation |
Cell Membrane |
CD42b
|
Zytomed Systems GmbH |
SP202 |
1 ml |
Concentrate |
RUO |
503-5024 |
-
|
Host |
Mouse |
Klon |
DF-T1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate (optional) |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Pluripotent human cell line K562 |
Lokalisation |
Cell Membrane |
CD43
|
Zytomed Systems GmbH |
DF-T1 |
1 ml |
Concentrate |
RUO |
MSK065 |
-
|
Host |
Mouse |
Klon |
DF-T1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate (optional) |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Pluripotent human cell line K562 |
Lokalisation |
Cell Membrane |
CD43
|
Zytomed Systems GmbH |
DF-T1 |
0.5 ml |
Concentrate |
RUO |
MSK065-05 |
-
|
Host |
Mouse |
Klon |
DF-T1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, CLL/SLL, or lymph node. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Stimulated human leukocytes |
Lokalisation |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2032ML |
-
|
Host |
Mouse |
Klon |
DF-T1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, CLL/SLL, or lymph node. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Stimulated human leukocytes |
Lokalisation |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2032MP |
-
|
Host |
Mouse |
Klon |
DF-T1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, CLL/SLL, or lymph node. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Stimulated human leukocytes |
Lokalisation |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2032MS |
-
|
Host |
Mouse |
Klon |
DF-T1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, CLL/SLL, or lymph node. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Stimulated human leukocytes |
Lokalisation |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2032MT |
-
|
Host |
Mouse |
Klon |
156-3C11 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Tonsil, breast cancer |
Verdünnung |
1:150 - 1:300 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cell membrane, cytoplasmic |
CD44
|
Biocare Medical |
156-3C11 |
0.1 ml |
Concentrate |
CE/IVD |
CM318A |
-
|
Host |
Mouse |
Klon |
156-3C11 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Tonsil, breast cancer |
Verdünnung |
1:150 - 1:300 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cell membrane, cytoplasmic |
CD44
|
Biocare Medical |
156-3C11 |
0.5 ml |
Concentrate |
CE/IVD |
CM318B |
-
|
Host |
Mouse |
Klon |
156-3C11 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
1 ml |
Concentrate |
CE/IVD |
MOB256 |
-
|
Host |
Mouse |
Klon |
156-3C11 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
0.1 ml |
Concentrate |
CE/IVD |
MOB256-01 |
-
|
Host |
Mouse |
Klon |
156-3C11 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
0.5 ml |
Concentrate |
CE/IVD |
MOB256-05 |
-
|
Host |
Mouse |
Klon |
156-3C11 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
6 ml |
Ready-to-use |
CE/IVD |
PDM172 |
-
|
Host |
Mouse |
Klon |
156-3C11 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Tonsil, breast cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cell membrane, cytoplasmic |
CD44
|
Biocare Medical |
156-3C11 |
6 ml |
Ready-to-use |
CE/IVD |
PM318AA |
-
|